UPL LINCOLN Date: 11° August, 2016 PHARMACEUTICALS LTD. . 1 To, | To, To, ‘The Manager, ‘The Department of Corporate | The Secretary, Listing Department, Service, Ahmedabad Stock Exchange National Stock Exchange of | Bombay Stock Exchange | Limited, | India Limited, Limited, Kamdhenu Complex, Opp. Exchange Plaza, C-1, Block-G, | Phirozeleejeebhoy Tower, | Sahjanand College, Nr. Polytechnic, Bandra - Kurla Complex, Dalal Street, Mumbai- 400001. | Panjarapole, Ahmedabad - 380 015, Bandra (E), Mumbai - 400 051. _ Scrip Code - LINCOLN ‘Scrip Code- 531633 Scrip Code -32428 Dear Sir, SUB. OUTCOME OF BOARD MEETING, With reference to the above, we would like to inform that the following is the outcome of the meeting of the Board of Directors of the Company held on Thursday, 11° August, 2016: 1h ME tg tae eee fe an ci of Bur ended on 308 2 URES a ior Gi seee alba baat Selo AURIS M/C. tah & Ca, on Sandee bined aucalncade tr te gener earn RTE Atay hf EE reco hae Yours faithfully, FOR LINCOLN PHARMACEUTICALS LIMITED Encl: As above Regd. Offoce “Lincoln House”, Science City Road, Sola, Ahmedabad-380 040. Gujarat, India Phone: +91-79-6777 8000 | Fax: +91-79-6777 8062 E-mail: info@lincolnpharma.com | Website : www lincolnpharma.com CIN : L242306J1995PLC024288 Factory : 10, 12,13, Trimul Estate, Near Khatraj Chokaci, P.O. Khatraj-382721. Ta: Kalol, Dist. Gandhinagar, (Gu Phone : 02764-665000 E-mail: khatraj@lincolnpharma.com / tincoln_khatraj@rediffmailcomLPL LINCOLN PHARMACEUTICALS LIMITED te } Rega. Office: "UNCOLN HOUSE" 8/h. Satyam Complex, Stience Cty Road, Sola, Ahmedabad - 380060. ‘wn: .24230611995P1C026288, Ph. No. +91-79-6777800, Fax: +91-79-6777 8062 LINcOoU ‘Website: wv tincolnpharms.com, E-Mall:info@incolnpharma.com nea ‘Statement of Consolidated and Standalone Unaudited Results for the Quarter ended on 30/06/2016 Tema ‘Guarertndea Year nea ‘aria ees | Year Ended Se aa SaeTTe | syosras | w/e | svos/ns | SVeEPAHT | suo3/xe | H/T | soso sated) | uses) | Unwusnee) | utes) | Unsuated) | Rete) | Ursudied) | uses) Teoma ron Opto Tet Slr ncons rom Corson hates aUT Toiear| sissass| sansa] —sasesva| veins] —asenze]| —sauase| —roassae] (uote Operating income ssus7|_estas[_2escs| ussiz9| sear] rons] zzzs0[ ursase [etlncome tron Opeaian at ‘Szcase| assis] —yssase|—aarstor] —yosas0| —nasnse| —soora0|—mayi038 acon ote conn aeorsr| esos | vasa | vara) seas] —isene| ase] Sse Telrad zeises| —7anssi| —nsosai| rouse) poor] —aeoite| —rconae| —is22507 (6 euceonen ante iss] zoese| as0s7| -aaass| __sise! ann| 43800] Tafenscveebenete erence Tasess| —oss3t| —st995| —aszrar| aia 77095] 333734] [nlfossrecaton and snorestion pare ‘eu| zee —susoe[ —anna7] gest] ena] ron] na titer expences Tiasae| —isysea| —toooas | —aenaat| —syran| —taaca7[ —asuas| cues [ot expenses 750.70] —un2738| 6 ss80r] —seaess2 | geei98| —gosoas| —easo29|—Pass074| J rete trom operas betas tha cae, Wace a Jnderceptionaliters 2 sors] sore] yososa| 430275] asnisa| —aess| srroo] asso get oe on aaary ar ana oo lepton tena (2 ser] sors] vmoso| azoa7s| ususa| ears] srroo| _assoae 7 Pret as aaa ee Har rane aa BADE lnceptonsl tones sassio| —o1sas| asxso| ssosse| usaso| russ] ros2e| 200871 3 [Profit os) rom oda aie beta TTT] 7ass30| Gisas|—wsso| —3366s6|-aseaso| aun | —7eene] 350571 So [Tevezene ssiae| —_zoeie| ress] snese]_assau[ au] 15796] a1] et roe at a aaa eis ar B=) ossz6| —s0.16| e548] aan] cumsae|—sos70| —eos20| Bares 12 [arsorcinary ue a ta prs ‘ol 020] 000] oan] ana] aol aol cad 2a |e ett os fore perea + pane] aoe] tensa nome | —aaiea| se 70 | —een30| aren i [Sareo Wo ow ofeecntes™ ao] ao] 00a] aol 900] cool aol ag ag Pte / (os ar tes minora ond share pra lon otareodater 2 5)" aosss| corm| esse! zgee2e| sooo] soss0| _aarast G7 eit ecu sare capitate ae BOT aeszon| —aestoa| este] aston] gatos] —iesian| iano | —Lenian Tai |tinnes Pr Sure etre and afer xvaprary Rema) = ole Soe et aa a em] 2s] em| usa ee] an] ar] aaa Ising fr Sare tre na ater asada Wane 2 of Be ac ot anaes a sro] zo] sos] sere} zs] sos] ars] sso 1 Theabove nae resuts were evewad by the Aust Comite and thereafter appraved bythe Sarda Decors of he Company a the meting heli on 13th Apu 2016 2 Fgurestorthe previous peod/ver ae being regrouped wherever necesay 3 Since the revenue rom ferent segment les than 10% of tal revenue segment wis result ar ot gen. 4 Statutory Auctors has card out ited review forthe quarry est for quarter ended 30.05.2016, 5 Convotdsted rests inclodesreaute of subsidiary Company. Fon ncourmamucyrags un o1n: 00108706) Pace: shmedsbad ste: 1/04/2016To Board of Directors of Lincoln Pharmaceuticals Limited Ahmedabad. We have reviewed the accompanying statement of unaudited Standalone financial results of Lincoln Pharmaceuticals Limited having its Registered Office at ‘Lincoln House”, Science City Road, Sola, Ahmedabad-380060, Gujarat for the quarter ended on 30/06/2016 except for the disclosures regarding ‘Public Shareholding’ and ‘Promoter and Promoter Group Shareholding’ which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors which has been prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting policies generally accepted in India, Our ‘esponsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited Primarily to inquiries of company personnel and an analytical Procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which itis to be disclosed, or that it contains any material misstatement, For, J.T. Shah & Co. Chartered Accountants (FRN No} 109616W) . 4 reo, ude. shany ——?— Partner [M.No.3983] Date: 11/08/2016 Place: Ahmedabad 201/202, Lalita Complex, 52/3, Rasala Marg, Nr Jan Temple, Navrangoura, Ahmedabed-380008, Phone : 264 444 20, 264.444 30, 264 444 40,265 604 40J.T. SHAH & CO. OUNTANTS To Board of Directors of Lincoln Pharmaceuticals Limited Ahmedabad, ‘We have reviewed the accompanying statement of unaudited Consolidated financial results of Lincoln Pharmaceuticals Limited having its Registered Office at ‘Lincoln House”, Science City Road, Sola, Ahmedabad-380060, Gujarat for the quarter ended on 30/06/2016. This statement is the responsibilty of the Company's Management and has been approved by the Board of Directors which has been prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of india. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion, ‘We did not review the financial statements of subsidiaries included in consolidated unaudited financial statement, whose consolidated unaudited financial statements reflect the total revenue of Rs.1717.58 Lacs and net profit of Rs.78.76 Lacs for the quarter ended on 30/06/2016. These financial results and other financial information have been reviewed by other auditors whose report has been furnished to us, and ur conclusion, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which itis to be disclosed, or that. it contains any material misstatement. For, J. T. Shah & Co. Chartered Accountants Place: Ahmedabad IM.No.3983] 201/202, Lalts Complex, 352/3, Rasala Marg, Nr. Jain Temple, Navrangpura, Ahmedabad-280003, Phone 264 444 20, 264 444 30, 264 444 40,265 604.40